Navigation Links
Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
Date:5/1/2009

BEIJING, May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading distributor of plant and animal nutrient products located in the People's Republic of China, today announced that one of the independently owned Yongye branded retail stores in its sales network set a new record for single day sales.

A Yongye branded retail store in Qianjiang City in Hubei Province sold 15,310 bottles of Shengmingsu plant nutrient product on April 30, 2009 for $30,000 in sales. This was the highest single day sales for a Yongye branded retail store in Yongye's history.

Yongye uses a community based distribution model through which a limited number of independent regional distributors distribute Yongye products to a network of independently owned Yongye branded retail stores and dedicated retail locations. There currently are approximately 2,000 Yongye branded retail stores, compared to 775 branded retail stores at the end of 2008. In addition to the branded retail stores, an additional 1,500 stores were recently added by the regional distributors to the retail sales network. Some of these stores are going through a certification process to become Yongye branded retail stores. A total of 3,500 retail locations are currently selling Yongye's Shengmingsu plant nutrient product.

The Company attributes some of the increased demand for its Shengmingsu plant nutrient product to promotional activities by its distributors and a Yongye advertising campaign which includes commercials on CCTV-7, China's national agriculture television channel, local agriculture television channels and newspapers.

"We are excited to have one of the Yongye branded retail stores set a new single day sales record. We believe that this record was set because of our marketing efforts which let farmers know about the effectiveness of our plant nutrient product," said Mr. Zishen Wu, CEO of Yongye Biotechnology International, Inc. "We are confident our new customers will be pleased with the results they achieve by using our plant product."

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    Contact:
    Yongye Biotechnology International, Inc.
    Mr. Larry Gilmore-VP of Corporate Strategy
    Phone: +86-8232-8866 x 8880
    E-mail: larry.gilmore@gmail.com

    CCG Investor Relations, Inc.
    Mr. Crocker Coulson, President
    Phone: +1-646-213-1915 (New York)
    E-mail: crocker.coulson@ccgir.com
   http://www.ccgirasia.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
2. Yongye Biotechnology Appoints New Chief Financial Officer
3. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
4. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
5. Yongye Biotechnology International to Expand its Network of Branded Stores
6. Yongye Biotechnology to Present at Roth Conference
7. Yongye Biotechnology Announces Record Third Quarter Results
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
10. Yongye Biotechnology International Raises $9.4 Million in Private Placement
11. Yongye Biotechnology International Announces Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
Breaking Biology Technology:
(Date:8/23/2017)... general public,s help is being enlisted in what,s thought to be the ... the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to ... The project's goal is to help advance scientific knowledge of the role ... The ...
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
Breaking Biology News(10 mins):